OncoMatch/Clinical Trials/NCT06102863

Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Is NCT06102863 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day); for atypical endometrial hyperplasia and endometrial carcinoma stage i.

Phase 2RecruitingPeking University People's HospitalNCT06102863Data as of May 2026

Treatment: statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day); — To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Statins in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Endometrial Cancer

Disease stage

Required: Stage IA

Prior therapy

Cannot have received: nursery therapy drugs (progesterone, GNRH-a) (progesterone, GNRH-a)

Exception: newly treated patients only

Newly treated patients: did not use any nursery therapy drugs (progesterone, GNRH-a)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify